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THE male survival disadvantages at all ages have been observed across human populations and even species. 
However, a full understanding of how the sex gap evolves 
with individual aging is still lacking (1). Both historical and 
contemporary human mortality data suggest that the sex gap 
in mortality is more pronounced in young adulthood (2) and 
decreases in postmenopausal ages due to a faster mortality 
rate acceleration for women after middle age that coincides 
with female fecundity decline (3). Studies of cause-specific 
mortality have further documented that cardiovascular dis-
eases (CVD) account for the majority of the sex gap in adult 
mortality and the decline of this gap at old ages (3–5). The 
sex differences in age- and cause-specific mortality suggest 
the hypothesis that the reduction in male survival disadvan-
tage in the old ages has a biological base, which cannot be 
directly tested using mortality data alone. To further under-
stand age variations in sex differentials in mortality, it is 
essential to compare age trajectories of physiological func-
tions between males and females that may be linked to sex-
specific mortality patterns (3,6).
Systemic inflammation and the metabolic disorders are 
important pathogenic mechanisms in a host of age-related 
conditions, such as arterial disease, diabetes, malignancies, 
and Alzheimer’s disease (7–10) and strongly predict mor-
tality (11–13). In addition, the aging and frailty process is 
characterized by a progressive dysregulation of the homeo-
static network and accelerated decline in function across 
multiple regulatory systems. The allostatic load (AL), a 
count of high-risk biological parameters across systems, 
has been increasingly utilized as a generalized indicator of 
cumulative burden of physiological dysregulation (14,15) 
and a powerful summary index of population frailty predict-
ing major health outcomes and mortality in the oldest ages 
(16,17). Sex and age differences in the lifetime burden of 
physiological dysregulation, therefore, should be examined 
as the major physiological mechanisms underlying sex 
differences in mortality and their age variations.
Although there are compelling theoretical explanations 
for sexual dimorphism in immune, metabolic, and multiple 
systems, extant empirical evidence mostly is based on small 
animal or clinical samples of single sex and/or limited age 
ranges (1,2,18–24). Recent population-based studies also 
suggest substantial sex differentials in several biomarkers 
(13,25–32), but they are largely focused on individual rather 
than overall burden of physiological disorders and are often 
restricted to small samples that are homogeneous in health 
status, demographic, or geographic characteristics. Age var-
iations in sex differences in biological functions contribute 
to the complexity of explanations but have not been system-
atically examined or rigorously modeled in population-
based samples. There is little knowledge from large 
nationally representative community samples of the distri-
butions and patterns of variations in major biological mea-
sures of inflammation, metabolic disorders, and cumulative 
physiological dysregulation among subgroups by sex and 
age within the same study population.
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This study fills these gaps through a precise characteriza-
tion of the sex differences in inflammation, metabolic syn-
drome (MetS), and AL across the adult life course in 
population data. We model both sex and age differences in 
these physiological variables to better understand the nar-
rowing sex gap in mortality in post-reproductive life span. 
We test the hypothesis that women enjoy immunological 
and metabolic advantages until menopause, but these 
advantages decrease in older ages. We focus on the sex and 
age patterns in biological parameters while adjusting for 
major social, behavioral, and morbidity factors frequently 
examined in previous research (8,15,29,31). The pathways 
by which these factors operate over the life course may be 
complicated and are topics of future examinations of the in-
terconnections between social and biological processes pro-
ducing sex phenotypic differences throughout the life span.
Methods
Study Population
The data come from the National Health and Nutrition 
Examination Survey (NHANES) conducted by the National 
Center for Health Statistics between 1988 and 1994 (III) 
and 1999 and 2006 (IV) that used a multistage stratified 
sampling design and include a representative cross-sectional 
sample of the noninstitutionalized U.S. population, with an 
oversample of older persons and minorities (33). This study 
includes about 38,000 individuals aged 17 years and older 
(age ranges 20+ for NHANES III and 17+ for NHANES 
IV) for whom interview, clinical examination, and labora-
tory tests are available. We examined 14 markers of physi-
ological functions listed in Table 1 including 3 markers of 
inflammation, 8 markers of metabolic functions, and 3 addi-
tional markers: serum homocysteine—an amino acid shown 
to be related to health and frailty (16); lung function—peak 
flow; and urinary function—creatinine clearance. The labo-
ratory measurements and assay procedures for all these 
markers have been described elsewhere (35,36).
The cutoff points for high-risk levels are based on clinical 
practice for 11 markers and empirically defined for 3 
(fibrinogen, peak flow, and creatinine clearance) as the top 
quartile at risk based on previous studies (16,26). The 
assays used to measure C-reactive protein (CRP) and fibrin-
ogen differed at the two study periods (NHANES IV values 
are higher). The laboratory doing the assays for CRP per-
formed an adjustment of NHANES IV values that produced 
highly comparable CRP values (33). We are not aware of a 
similar adjustment for fibrinogen, so we adopted wave- 
specific top quartile cutoff points. We found no difference in 
results using different cutoff points for CRP (3.0 and 4.0 
mg/L) and the same cutoff point for fibrinogen (top quartile 
for NHANES III), which suggests low sensitivity of find-
ings to the choice of cutoff points. We also conducted 






p Value*N M SD
% High  
Risk N M SD
% High  
Risk
Inflammation
 C-reactive protein >3.0 mg/dL 18,052 0.3 0.8 19.8 19,909 0.5 0.8 34.4 <.001
 Plasma fibrinogen ≥341/411 mg/dL† 7,289 340.4 85.0 21.5 7,751 355.5 85.9 29.1 <.001
 Urinary albumin ≤3.5 mg/mL 18,241 19.7 54.2 22.0 20,251 17.7 47.7 27.0 <.001
Inflammation index (age 40+) 6,952 0.7 0.8 7,239 1.0 0.9 <.001
Metabolic factors
 Waist circumference >102/88 cm‡ 18,139 98.2 15.0 36.6 19,942 92.2 16.0 55.3 <.001
 Systolic blood pressure ≥130 mmHg 17,264 124.3 16.5 15.5 18,950 121.4 21.6 17.8 <.001
 Diastolic blood pressure ≥85 mmHg 17,263 73.1 13.2 9.0 18,949 69.5 12.9 4.9 <.001
 Serum triglycerides ≥150 mg/dL 14,607 154.6 160.8 34.8 16,155 126.6 102.9 25.6 <.001
 HDL cholesterol <40 mg/dL 18,026 46.9 13.3 30.2 19,845 57.3 16.1 10.7 <.001
 Fasting glucose ≥110 mg/dL 12,438 102.6 29.8 15.7 13,727 98.6 30.7 11.8 <.001
 Body mass index ≥30 kg/m2 18,883 27.6 5.6 26.9 20,935 27.8 7.0 31.3 <.001
 Glycated hemoglobin (HbA1c) ≥6.4% 18,258 5.5 0.9 6.6 20,204 5.4 0.9 5.8 .031
Metabolic syndrome 9,317 0.2 0.4 10,163 0.1 0.4 <.001
Other physiological functions <.001
 Serum homocysteine ≥15 mmol/L 13,099 9.4 4.2 5.0 14,882 8.0 4.1 3.8 <.001
 Peak flow (largest value) <2113 mL 7,724 3,447.7 1,484.1 19.4 8,735 2,691.8 1,179.5 32.5 <.001
 Creatinine clearance <66.7 mg/dL 18,484 152.6 85.6 16.0 20,401 111.2 75.8 33.8 <.001
Allostatic load 6,775 2.3 1.9 7,710 2.6 1.9 <.001
Notes: Fibrinogen was only measured for respondents aged 40 years and older. The glucose measures require fasting and have smaller samples. Homocysteine 
was assayed only in the second half of NHANES III (1991–1994). And peak flow was not available for NHANES IV. NHANES = National Health and Nutrition 
Examination Survey. HDL = High Density Lipoprotein.
* Top quartile high-risk cutoff points for NHANES III and IV, respectively.
† Clinical high-risk cutoff points for men and women, respectively—the clinical criteria for high risk are only sex specific (34).
‡ Test for sex difference in the means (two sided). An a level of .0027 is used to adjust for multiple comparisons using the Bonferroni method. All sex differences 
are significant with the exception of mean HbA1c. Results for sex difference in the % high risk are similar. 
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robustness analyses by allowing the high-risk cutoff points 
vary with age in order to take into account of the possibility 
that the common at-risk levels may not apply to (ie, be too 
high for) the oldest ages. First, we compared the current cut-
off points with those published in previous studies of older 
adults aged 40+ (26) and 65+ years (37) from the same 
NHANES data and older adults aged 70–79 years from a 
different data set (17). The cutoff points are the same for 
most biomarkers common to all studies, with the exception 
of blood pressure, triglycerides, and HbA1C whose cutoff 
points are actually slightly lower in our study. We changed 
these cutoff points to those used in previous studies (dia-
stolic blood pressure ≥90, systolic blood pressure ≥ 140, 
triglycerides ≥200, and HbA1C ≥7.1). Second, we em-
pirically defined the cutoff points as the top quartile at risk 
for all markers in age-specific groups (<60 and ≥60). Third, 
because the potential change in risk level mostly pertains to 
the oldest ages due to increasing debility and 
impending mortality, we eliminated respondents aged 85+ 
years from the samples. None of the above analysis showed 
any substantive change in the results. Based on common 
practice and for comparability, we used the cutoff points 
shown in Table 1 for all ages in the final analyses reported 
here.
We constructed summary indices based on the aforemen-
tioned high-risk cutoff points. The burden of inflammation 
index is the sum of the positive indicators and ranges from 0 
to 3. The MetS is defined based on the National Cholesterol 
Education Program/Adult Treatment Panel III criteria (38) 
as positive for those having three or more of five metabolic 
disorders: abdominal obesity, high blood pressure, hypertri-
glyceridemia, low High Density Lipoprotein cholesterol, and 
high fasting glucose. Following previous studies, we opera-
tionalized the AL as a count of high-risk biological param-
eters across multiple systems, including markers of 
inflammation, cardiovascular and metabolic functions, lung 
function, and renal function, that is, a sum of positive indi-
cators of all 14 markers above. We present results using the 
13-count AL (without fibrinogen) to include all ages (addi-
tional analyses show no difference in results from those us-
ing the 14-count AL).
In addition to sex and age variables, covariates in the final 
analysis are shown in Table 2 and include social demo-
graphic characteristics, such as race/ethnicity and marital 
status; socioeconomic status indicated by education and 
family income in 1991 dollars; health behaviors indicated by 
cigarette smoking and alcohol use; morbidity indicated by 
the number of chronic conditions including 14 self-reported 
chronic illnesses: angina, arthritis, asthma, bronchitis, dia-
betes, emphysema, heart attack, heart failure, cancer, stroke, 
hip fracture, osteoporosis, spine fracture, and wrist fracture; 
and medications including female hormone therapy, hyper-
tension, and cholesterol medication. Sample characteristics 
(weighted) based on these covariates for all and by age and 
sex are shown in Table 2. Respondents who lacked mea-
sures of the biomarkers for summary indices and covariates 
Table 2. Characteristics (weighted) of the Allostatic Load Sample* in National Health and Nutrition Examination Survey (1988–2006)
Variable All (N = 11,600)
All Ages  
(N = 5,347)
Men
All Ages  
(N = 6,253)
Women
17–59 y  
(N = 3,531)
60+ y  
(N = 1,816)
17–59 y  
(N = 4,375)
60+ y  
(N = 1,878)
Race %
 Non-Hispanic White 73.9 (43.9) 74.4 (43.6) 72.0 (44.9) 84.1 (36.6) 73.4 (44.2) 70.3 (45.7) 83.3 (37.3)
 Non-Hispanic Black 10.2 (30.2) 9.4 (29.3) 10.3 (30.4) 6.3 (24.4) 10.8 (31.1) 11.9 (32.4) 7.7 (26.6)
 Mexican American 6.7 (25.1) 7.5 (26.3) 8.6 (28.0) 3.2 (17.6) 6.1 (23.8) 7.0 (25.6) 2.9 (16.8)
 Other 9.1 (28.8) 8.6 (28.1) 9.2 (28.9) 6.4 (24.5) 9.6 (29.5) 10.8 (3.1) 6.1 (23.9)
Education %
 0–8 y 3.3 (18.0) 3.6 (18.5) 2.8 (16.4) 6.6 (24.8) 3.2 (17.6) 2.1 (14.3) 6.7 (25.0)
 9–12 y 43.7 (49.6) 43.7 (49.6) 43.2 (49.5) 46.0 (49.9) 43.7 (49.6) 40.1 (49.0) 55.3 (49.7)
 13+ y 53.0 (49.9) 52.3 (49.9) 54.1 (49.8) 47.4 (49.9) 53.1 (49.9) 57.8 (49.4) 38.0 (48.6)
Family income (median in 1991 $) 30,283 35,961 37,500 30,283 30,283 32,500 22,712
Marital status %
 Married 66.5 (47.2) 70.1 (45.8) 67.4 (46.9) 81.0 (39.3) 62.9 (48.3) 66.3 (47.3) 52.1 (50.0)
 Widowed 5.8 (23.5) 2.2 (14.7) 0.6 (7.5) 8.7 (28.2) 9.4 (29.2) 1.8 (13.1) 33.9 (47.4)
 Divorced/separated 11.6 (32.0) 9.3 (29.0) 9.6 (29.4) 8.1 (27.2) 13.9 (34.6) 15.0 (35.7) 10.3 (30.5)
 Never married 16.1 (36.7) 18.4 (38.7) 22.5 (41.8) 2.2 (14.8) 13.8 (34.5) 17.0 (37.6) 3.6 (18.6)
Cigarette smoking %
 Never 48.3 (50.0) 40.2 (49.0) 43.4 (49.6) 27.7 (44.8) 56.2 (49.6) 56.4 (49.6) 55.3 (49.7)
 Former 25.7 (43.7) 30.2 (45.9) 23.3 (42.3) 57.4 (49.4) 21.4 (41.0) 18.1 (38.5) 32.1 (46.7)
 Current 25.9 (43.8) 29.6 (45.6) 33.3 (47.2) 14.8 (35.5) 22.4 (41.7) 25.5 (43.6) 12.7 (33.3)
Alcohol use (mean days per month) 5.1 (8.2) 6.8 (9.2) 6.6 (8.7) 7.6 (10.9) 3.3 (6.6) 3.2 (6.1) 3.6 (7.9)
Number of chronic conditions 0.9 (1.2) 0.8 (1.2) 0.7 (1.0) 1.6 (1.5) 1.0 (1.2) 0.7 (1.0) 1.8 (1.5)
Female hormone therapy % 25.4 (43.5) 25.3 (43.5) 18.2 (38.6) 48.3 (50.0)
Hypertension medication % 17.5 (38.0) 18.9 (39.1) 9.9 (29.8) 40.6 (49.1) 16.2 (36.8) 10.4 (30.6) 46.0 (50.0)
Cholesterol medication % 10.0 (30.1) 10.8 (31.0) 7.1 (25.6) 25.3 (43.5) 9.3 (29.0) 4.9 (21.7) 23.3 (42.2)
* Characteristics for the inflammation index and metabolic syndrome samples are similar and not presented; only variables that are common across two waves are 
included.
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are excluded from the analytic samples. Compared to those 
with complete data on biomarkers, those with missing data 
were older, more likely to be widowed, and had more 
chronic illnesses. These individuals either had difficulties 
completing parts of the examination due to incapacity or 
simply refused to provide samples (33). In all, the combined 
NHANES samples provide sufficient numbers of observa-
tions for multivariate analyses. And the exclusion of older 
and frailer persons produces more conservative estimates.
Statistical Analysis
We first conducted descriptive analyses to examine distribu-
tions of measured biological functions by sex using the t test 
and by sex and age using analysis of variance and the c2 test. 
We then estimated multivariate regression models to assess the 
parametric relationships of sex and age with biological vari-
ables. We used log transformations of continuous outcomes to 
account for skewed sampling distributions. Results show im-
proved model fit to data on all markers using the log transfor-
mation. We estimated ordinal logit and Poisson regressions for 
the inflammation index, logistic regression models for MetS, 
and Poisson and negative binomial models for the AL. We used 
various codings of the age variable (continuous and categori-
cal) and tested for its polynomial functional forms. We con-
ducted stepwise regressions that brought in measures one at a 
time. None of these analyses show substantively different re-
sults with regard to the directions and magnitudes of regression 
coefficients and significance tests on either coefficients or the 
models as a whole. We chose the best model specifications 
based on tests of statistical significance of coefficient estimates 
and model fit statistics using Bayes Information Criterion, a 
generalized test of model fit adjusting the impact of model 
dimensions on model deviance (smaller is better). We fur-
ther examined social, behavioral, and morbidity factors in 
relation to summary biological indices to understand how 
they may account for sex and age differences observed. All 
statistical analyses were performed using Stata 10.0. We 
used the Bonferroni method for adjustment of p values due 
to the multiple tests that were conducted (39). And we ad-
justed for the complex survey designs using sampling 
weights for descriptive analysis and the “svy” procedures 
for the regression analysis.
Results
Both descriptive and multivariate regression analyses 
show substantial and highly significant sex differences, 
nonlinear age variations, and sex differences in age trajecto-
ries for all individual markers and summary indices 
of physiological dysregulation. The results on individual 
markers of inflammation, metabolic, and other functions are 
largely consistent with those on the corresponding indices. 
We focus on the modeling results for the summary indices 
and refer interested readers to the online supplement for 
detailed results for all 14 individual markers. A brief 
description of the Supplementary Figures is in order here. 
Supplementary Figures A–C present the observed data on 
biomarkers of inflammation, metabolic functions, and other 
functions together with smoothed age curves from the best-
fitting models using polynomials of age (eg, age, age2, age3, 
etc.), sex, and their interactions. The regression coefficients 
for these effects (not shown) are all highly significant and 
do not differ significantly by wave. Results hold after 
adjusting for other covariates.
Table 3 presents the regression coefficient estimates from 
the best-fitting models of summary indices, including ordi-
nal logit regressions of the inflammation index, the logistic 
regressions of the MetS, and the negative binomial regres-
sions of the AL. Models 1a–3a present the crude associa-
tions of age, sex, and age by sex interaction with outcome 
variables. Models 1b–3b present the adjusted associations 
controlling for social, behavioral, and morbidity risk fac-
tors. There are significant quadratic age effects for all three 
indices, suggesting increases in physiological disorders 
with age that decelerate at older ages. The age patterns of 
sex differentials in physiological dysregulation generally 
show gradual decreases of the sex gaps starting in the early 
60’s and support the hypothesis of a postmenopausal reduc-
tion of female physiological advantages. The patterns of sex 
difference and age variation vary by biological functions 
and other risk factors (detailed results of all the control var-
iables are available upon request).
Model 1a shows that men have a lower inflammation bur-
den than do women (odds ratio = 0.24, 95% confidence 
interval : 0.15–0.38, p < .001), but the sex gap decreases with 
age, as indicated by the sex by age interaction (p = .001) and 
the converging sex gaps in the age curves in Figure 1. Model 
1b shows that adjusting for other covariates reduces the age, 
sex, and age by sex interaction effects in magnitude and/or 
significance level. Model 2a shows that the odds of experi-
encing the MetS are more than four times higher for men 
than for women (odds ratio = 4.38, 95% confidence interval = 
2.91–6.59, p < .001), but this difference decreases with age 
(p < .001 for the sex by age interaction), as illustrated by 
Figure 2 in which the sex gap in the probability of MetS 
converges and reverses later in life. The results hold and 
become stronger in Model 2b with adjustment of covariates. 
Model 3a shows that men are expected to have lower AL 
than women, holding age constant (incidence rate ratio = 
0.92, 95% confidence interval = 0.89–0.95, p < .001). The 
sex difference decreases somewhat after adjusting for other 
covariates (Model 3b). Although the sex by age interaction 
term is not statistically significant in this model of continu-
ous age effects, it is highly significant in the model using a 
dichotomous age variable (age < 60 vs 60+, results not 
shown), suggesting a widening sex gap in persons aged 60 
years and older (p = .008 for the sex by age interaction). 
Figure 3 further compares the adjusted means by sex and 
age groups. It shows that the AL increases with age more for 
women than for men, leading to a larger female excess in 
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postmenopausal ages that persists after adjustment of other 
covariates (p = .025 for the sex by age interaction).
Models 1b–3b also adjusted for interactions of risk fac-
tors with sex and age that appear significant (such as obesity 
and smoking) and show improved model fit over Models 
1a–3a, respectively, but the residual sex differences and age 
variations remain statistically significant. We examined 
additional covariates, including health insurance, diet and 
nutrition, physical activity, and social integration (religious 
attendance, ties with friends and family relatives, and mem-
bership in social organizations) in these models. Because 
variables of social integration are not available in the 
NHANES IV, models including these variables can only be 
estimated using the NHANES III data. The age and sex 
effects remain robust in models of inflammation, MetS, and 
AL even after adjusting for additional covariates. Excluding 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































40 50 60 70 80 90+
Age
observed: male observed: female
predicted: male predicted: female
Figure 1. Sex difference and age variation in inflammation index. Note: In-
stead of the individual observations that would preoccupy the graph due to their 
large number, the observed data represent the mean for each age. The same ap-

















20 30 40 50 60 70 80 90+
Age
observed: male observed: female
predicted: male predicted: female
Figure 2. Sex difference and age variation in probability of metabolic 
syndrome.
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infections) and controlling for the effect of estrogen medi-
cations in women does not change the results.
Discussion
It is unclear from previous studies whether genetic and 
hormonal influences contribute to greater male or female 
preponderance in major physiological determinants of hu-
man longevity and how they vary with age. In addition, few 
studies have attempted at simultaneous assessments of sex 
and age differences in multiple domains of biological func-
tions with statistical adjustments for other risk factors. This 
study addresses these issues and provides population-based 
evidence for important sex differences in the age trajecto-
ries of major markers of immune and metabolic systems 
and the AL.
Women show higher mean levels of inflammatory mark-
ers and overall burden but slower rates of increase in inflam-
mation with age. This suggests the complicated nature of 
the interaction of sex-specific reproductive anatomy and 
functions with vascular inflammatory processes. The 
female sex hormone estrogen has been hypothesized to have 
a protective anti-inflammatory effect that may improve host 
resistance to degenerative diseases (24). It has also been 
proposed that endogenous estrogens may reduce the risk of 
CVD in females by modulation of the fibrinolytic factors 
much more than by affecting the levels of inflammatory 
markers or coagulation factors (24). The female reproduc-
tive senescence due to the exhaustion of ovarian oocytes 
and ovarian steroid loss may interact with these processes 
and contribute to the age changes in inflammation. The 
higher inflammation but lower risk of CVD in women 
than in men also seems to suggest the use of sex-specific 
high-risk cutoff points for inflammatory markers in future 
research (25,27).
There are large male excesses in a host of metabolic 
disorders and the overall MetS that disappear in late life. 
Recent research points to the importance of long-lasting 
effects of female sex hormone changes. Fluctuations in 
estrogens especially in 17b-estradiol (E2) during the men-
strual cycle and pregnancy induce endocrine and vascular 
challenges in women that decrease vascular resistance and 
arterial blood pressure, increase cardiac output by as much 
as 40%, and create optimal cardiovascular compliance 
comparable with the effects of exercise and even the circu-
latory efforts of athletes (24). The “jogging female heart” 
may thus protect women against CVD risks during repro-
ductive years. Postmenopausal increase in these risks in 
women then follow their physiological changes with age as 
a result of reductions of estrogen and increased fat storage 
and deposition of fat in abdominal areas. There is a lag of 
5–10 years between the average age of menopause and no-
ticeable accelerations of female physiological dysregula-
tion in our data. Although the wide use of estrogen 
replacement therapies among U.S. women could have con-
tributed to the  delayed deterioration (1,3), the fact that the 
timing of change is consistent with those in mortality 
shown from historical data on other industrialized coun-
tries (3) suggests that this may reflect the latency of physi-
ological disorders in the absence of estrogen and related 
modulating factors.
Women exhibit a higher cumulative burden of physiolog-
ical dysregulation across multiple systems indicated by the 
AL than men. Although such difference is small before 
menopause, it grows larger afterward. The relationship be-
tween the AL and age can be used to characterize the rate of 
biological aging (17). A faster rate of increase in the AL 
with age in women compared with men indicates the lack of 
a female biological aging superiority hypothesized in a pre-
vious study of Japanese clinical sample (32). In fact, this 
finding, together with that of the MetS, indicates the loss of 
female advantages in various biological functions at older 
ages that are highly consistent with the reduction of sex dif-
ference in all-cause and CVD mortality with age. Reduction 
of the female excess in inflammation with age, on the other 
hand, may be one key factor that contributes to a persistent 
female advantage in survival into the old age. We would like 
to caution that the AL should not be interpreted as merely a 
sum or linear combination of individual systems it encom-
passes, but rather as an indicator of biological complexity of 
the comorbidity process and general vulnerability to stress, 
as suggested by recent literature on the measurement of 
frailty (40,41). The summary indices of inflammation, 
MetS, and AL, therefore, should be considered as distinct 
aspects of physiological dysregulation and results on their 
sex and age variations should be interpreted accordingly.
These findings on sex differences in age-specific changes 
in physiological dysregulation also have implications for 
profound sex differences in prevalence of functional dis-
ability in old ages (42). Chronic inflammation, metabolic 
disorders, and a high AL impose burdens on physical func-
tions, the accumulation of which initiate the progressive 




























Figure 3. Sex difference and age variation in allostatic load (AL).
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as the end product (43). And higher levels and faster rates of 
deterioration of all three indices in older ages correspond 
well to the higher prevalence of disability and steeper de-
clines in physical functions for women than for men docu-
mented in previous research. Given the longer female life 
expectancy, interventions aimed at promoting healthy aging 
and quality of life for women should thus be targeted at 
eliminating these specific predisease pathways to disability.
We find that differential exposures and vulnerabilities to 
social status and behaviors partially account for the sex dif-
ferences in age patterns of various biological functions. In 
addition, the fact that the associations of behavioral factors 
such as smoking and obesity with certain indicators of 
physiological dysregulation such as inflammation and MetS 
vary by sex and/or age groups should be taken into account 
in future investigations. A considerable amount of sex and 
age variation in most physiological parameters is unex-
plained by the inclusion of the above and other factors, 
however. This provides a most compelling reason for more 
in-depth examination of the biological base for sex differ-
ences and their age changes. For example, recent biological 
aging research builds on the free radical theory of aging to 
elucidate the mechanism by which estrogens may affect 
longevity. There is evidence of more measured oxidative 
stress damage to DNA in males than in females (24) and 
that 17b-estradiol upregulates antioxidant gene expression 
and thus protects females against aging-related diseases 
(44,45). These are promising directions for future studies of 
longevity. It is challenging, however, to test the mechanisms 
found at the cellular level with data measured at the popula-
tion level as it involves studies across levels of organization 
(1). Because these hypotheses have been generated from 
studies of animals, human cells, and organs in experimental 
settings that are largely detached from social life experi-
ences, the question of how sex differences arise from inevi-
table interactions between the physical and social worlds in 
human populations remains to be addressed.
This study is based on cross-sectional data as prospective 
data containing multiple biomeasures are rare. The age trajec-
tories revealed here then represent the distributions by age of 
the surviving population from cohorts born earlier. There are 
two caveats in the interpretation of results. First, the mortality 
risk and hence force of selection with respect to physiological 
status is greater with the increase of age. Therefore, the ac-
celeration of physiological dysregulation with age is reduced 
by selective survival. Selective survival is not the only expla-
nation, however, because the age patterns vary by physiologi-
cal measures and adjustment of other risk factors. If selection 
slowed down the age increase in frailty for all groups, one 
should have observed similar downward age patterns in both 
sexes. But this is not observed in findings of MetS or AL. A 
related issue is that selection may have decreased population 
heterogeneity later in life (41,46). If this is the case, one 
should have observed smaller gaps in men and women in old 
age. But instead the gap increases for the AL after the age of 
60. Second, the age variations may be confounded with 
cohort differences. There is evidence that recent cohorts 
(especially those born after 1955) show increases in obesity 
rates (47), which likely inflates the age-specific estimates of 
metabolic disorders for the younger age groups in the current 
study samples. Modeling the age, period, and cohort effects is 
a difficult methodological issue and requires additional time 
periods of data (48). In sum, collection and analysis of longi-
tudinal data on biomarkers should be a priority for future 
research because they would facilitate the test of selection 
effect and produce estimates of within-cohort age trajectories 
that represent true developmental changes with age and hence 
help to distinguish aging and cohort effects.
Limitations in the measurement of biological variables 
invite future investigations using a broader spectrum of 
markers. Although the NHANES is among the few national 
surveys that offer a wide range of indicators of biological 
functions, many other biomarkers are not currently included 
such as other proinflammatory cytokines (eg, interleukin-6) 
and physiological stress responses in terms of stress hor-
mones regulated by the hypothalamic–pituitary–adrenal axis 
and the sympathetic nervous system. There may be sex dif-
ferences in biobehavioral response to stress (“fight-or-flight” 
for males vs “tend-and-befriend” for females) that have a 
neuroendocrine basis which may modulate risks for stress-
related disorders and survival (49). Including measurement 
of these responses is essential to a more comprehensive char-
acterization of sex difference in physiology in population.
This study presents some initial evidence of the potential 
physiological pathways through which age changes in sex 
mortality gaps occur. The full establishment of the links 
between physiological processes and sex differences in age-
specific mortality at the individual level requires additional 
analysis of mortality follow-up data, which we now are 
conducting.
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